Submission for OMB Review; 30-Day Comment Request; Surveys and Interviews To Support an Evaluation of the Innovative Molecular Analysis Technologies (IMAT) Program (NCI), 33263-33264 [2016-12294]

Download as PDF 33263 Federal Register / Vol. 81, No. 101 / Wednesday, May 25, 2016 / Notices Correction In the Federal Register of April 27, 2016, in FR Doc. 2016–09812, the following corrections are made: 1. On page 24828, in the first column, under the heading ‘‘Key Dates’’, the correct Earliest Anticipated Start Date should read as ‘‘Earliest Anticipated Start Date: August 15, 2016’’. 2. On page 24829, in the first column, under the heading ‘‘Project Period’’, the correct paragraph should read as ‘‘The project period will be for three (3) years and will run consecutively from August 15, 2016 to August 14, 2019’’. Dated: May 11, 2016. Elizabeth A. Fowler, Deputy Director for Management Operations, Indian Health Service. [FR Doc. 2016–12303 Filed 5–24–16; 8:45 am] BILLING CODE 4165–16–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Submission for OMB Review; 30-Day Comment Request; Surveys and Interviews To Support an Evaluation of the Innovative Molecular Analysis Technologies (IMAT) Program (NCI) Under the provisions of Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Cancer Institute, the National Institutes of Health, has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below. This proposed information collection was previously published in the Federal Register on March 23, 2016, Vol. 81, Page 15541 and allowed 60-days for public comment. The purpose of this notice is to allow an additional 30 days for public comment. The National Cancer Institute (NCI), National Institutes of Health, may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, SUMMARY: presents a rich and unique opportunity likely to serve institutes across the National Institutes of Health (NIH), and perhaps other federal agencies, considering the costs and benefits of directing resources towards supporting technology development. An award through the NIH Evaluation Set-Aside program to support this evaluation, for which NIH-wide relevance is a principle element of determining merit for support, is testament to this. The evaluation serves as an opportunity to gauge the impact of investments in technology development and also to assess the strengths and weaknesses of phased innovation award mechanisms. Prior approval from OMB allowed for extensive surveys and interviews already, and this extension is requested to accommodate unforeseen delays in collecting the remaining information. Like all institutes and centers (ICs) of the NIH, NCI seeks opportunities for improving their programs’ utility for the broad continuum of researchers, clinicians and ultimately patients. NCI Acting Director Douglas Lowy and other leadership across NCI, as well as the NCI Board of Scientific Advisors, will be the primary users of the evaluation results. Findings are primarily intended for considering the long-term strategy to support innovative technology development and how to more efficiently translate emerging capabilities through such technologies into the promised benefits for cancer research and clinical care. Interviews with grantees, program officers, review officers, and other NIH awardees make up a crucial component of the evaluation plan and will largely follow set survey protocols. Specific near-term aims include the use of this information to consider the utility of continued investment through existing solicitations and in strategic planning generally for institute support for innovative technology development. OMB approval is requested for 1 year. There are no costs to respondents other than their time. The total estimated annualized burden hours are 233. revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number. Direct Comments to OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, OIRA_submission@ omb.eop.gov or by fax to 202–395–6974, Attention: NIH Desk Officer. Comment Due Date: Comments regarding this information collection are best assured of having their full effect if received within 30 days of the date of this publication. FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data collection plans and instruments, or request more information on the proposed project, contact: Anthony Dickherber, NCI Center for Strategic Scientific Initiatives, 31 Center Drive, Rm10A33, Bethesda, MD 20892 or call non-toll-free number 301–547–9980 or Email your request, including your address to: dickherberaj@mail.nih.gov. Formal requests for additional plans and instruments must be requested in writing. Proposed Collection: Surveys and Interviews to Support an Evaluation of the Innovative Molecular Analysis Technologies (IMAT) Program (NCI), 0925–0720, Expiration Date 5/31/2016— EXTENSION, National Cancer Institute (NCI), National Institutes of Health (NIH). Need and Use of Information Collection: The purpose of the proposed evaluation is to pursue a comprehensive process and outcome assessment of the 15-year old Innovative Molecular Analysis Technologies (IMAT) program. While the program consistently offers promising indicators of success, the full program has not been evaluated since 2008, and never in as comprehensive a manner as has been formulated in the current evaluation plan. An outcome evaluation of the long-standing National Cancer Institute’s (NCI) IMAT program ESTIMATED ANNUALIZED BURDEN HOURS Number of respondents Average burden per response (in hours) Number of responses per respondent Total annual burden (in hours) mstockstill on DSK3G9T082PROD with NOTICES Form name Type of respondents Interview—IMAT Grantee ................. Web-based Survey—Technology Grantees. 18 379 1 1 1 30/60 18 190 Interview—Tech End-Users .............. IMAT Awardees ................................ IMAT Awardees; Other NIH Awardees representing comparison group. Technology End-Users ..................... 50 1 30/60 25 Totals ......................................... ........................................................... 447 447 ........................ 233 VerDate Sep<11>2014 20:19 May 24, 2016 Jkt 238001 PO 00000 Frm 00066 Fmt 4703 Sfmt 4703 E:\FR\FM\25MYN1.SGM 25MYN1 33264 Federal Register / Vol. 81, No. 101 / Wednesday, May 25, 2016 / Notices Dated: May 19, 2016. Karla Bailey, Project Clearance Liaison, National Cancer Institute, NIH. [FR Doc. 2016–12294 Filed 5–24–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings mstockstill on DSK3G9T082PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Population Sciences and Epidemiology Integrated Review Group; Cancer, Heart, and Sleep Epidemiology B Study Section. Date: June 16–17, 2016. Time: 8:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Rd. NW., Washington, DC 20015. Contact Person: Ellen K Schwartz, EDD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3144, MSC 7770, Bethesda, MD 20892, 301–828– 6146, schwarel@mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Psychosocial Risks and Disease Prevention. Date: June 21, 2016. Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting). Contact Person: Weijia Ni, Ph.D., Chief/ Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3100, MSC 7808, Bethesda, MD 20892, 301–594– 3292, niw@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Non-HIV Diagnostics, Food Safety, Sterilization/Disinfection, and Bioremediation. Date: June 23–24, 2016. VerDate Sep<11>2014 20:19 May 24, 2016 Jkt 238001 Time: 8:00 a.m. to 5:30 p.m. Agenda: To review and evaluate grant applications. Place: Sheraton La Jolla Hotel, 3299 Holiday Court, La Jolla, CA 92037. Contact Person: Gagan Pandya, Ph.D., Scientific Review Officer, National Institutes of Health, Center for Scientific Review, 6701 Rockledge Drive, RM 3200, MSC 7808, Bethesda, MD 20892, 301–435–1167, pandyaga@mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Topics in Non-HIV Microbial Diagnostic and Detection Research. Date: June 24, 2016. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Sheraton La Jolla Hotel, 3299 Holiday Court, La Jolla, CA 92037. Contact Person: Gagan Pandya, Ph.D., Scientific Review Officer, National Institutes of Health, Center for Scientific Review, 6701 Rockledge Drive, RM 3200, MSC 7808, Bethesda, MD 20892, 301–435–1167, pandyaga@mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Innovative Immunology Research. Date: June 24, 2016. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Renaissance Arlington Capital View Hotel, 2800 South Potomac Ave., Arlington, VA 22202. Contact Person: Deborah Hodge, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4207 MSC 7812, Bethesda, MD 20892, (301)435– 1238, hodged@mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Microbiome and Related Sciences. Date: June 24, 2016. Time: 10:30 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: Courtyard by Marriott Downtown Silver Spring, 8506 Fenton Street, Fenton Street, Silver Spring, MD 20910. Contact Person: Aiping Zhao, MD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Rm 2188 MSC7818, Bethesda, MD 20892–7818, (301) 435–0682, zhaoa2@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR13–231: Phenotyping Embryonic Lethal Knockout Mice. Date: June 24, 2016. Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Maqsood A Wani, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2114, MSC 7814, Bethesda, MD 20892, 301–435– 2270, wanimaqs@csr.nih.gov. PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 Name of Committee: Center for Scientific Review Special Emphasis Panel; Collaborative Applications: Adult Psychopathology. Date: June 24, 2016. Time: 1:00 p.m. to 1:30 p.m. Agenda: To review and evaluate grant applications. Place: Marines’ Memorial Club and Hotel, 609 Sutter Street, San Francisco, CA 94102. Contact Person: Serena Chu, Ph.D., Scientific Review Officer, BBBP IRG, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3178, MSC 7848, Bethesda, MD 20892, 301–500– 5829, sechu@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Alzheimer’s Disease Pilot Clinical Trials. Date: June 24, 2016. Time: 1:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Mark Lindner, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3182, MSC 7770, Bethesda, MD 20892, 301–915– 6298, mark.lindner@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: May 19, 2016. Carolyn Baum, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–12295 Filed 5–24–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Mental Health; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Mental Health Special Emphasis Panel; E:\FR\FM\25MYN1.SGM 25MYN1

Agencies

[Federal Register Volume 81, Number 101 (Wednesday, May 25, 2016)]
[Notices]
[Pages 33263-33264]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-12294]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Submission for OMB Review; 30-Day Comment Request; Surveys and
Interviews To Support an Evaluation of the Innovative Molecular
Analysis Technologies (IMAT) Program (NCI)

SUMMARY: Under the provisions of Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National Cancer Institute, the National
Institutes of Health, has submitted to the Office of Management and
Budget (OMB) a request for review and approval of the information
collection listed below. This proposed information collection was
previously published in the Federal Register on March 23, 2016, Vol.
81, Page 15541 and allowed 60-days for public comment. The purpose of
this notice is to allow an additional 30 days for public comment. The
National Cancer Institute (NCI), National Institutes of Health, may not
conduct or sponsor, and the respondent is not required to respond to,
an information collection that has been extended, revised, or
implemented on or after October 1, 1995, unless it displays a currently
valid OMB control number.
Direct Comments to OMB: Written comments and/or suggestions
regarding the item(s) contained in this notice, especially regarding
the estimated public burden and associated response time, should be
directed to the: Office of Management and Budget, Office of Regulatory
Affairs, OIRA_submission@omb.eop.gov or by fax to 202-395-6974,
Attention: NIH Desk Officer.
Comment Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 30 days
of the date of this publication.

FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data
collection plans and instruments, or request more information on the
proposed project, contact: Anthony Dickherber, NCI Center for Strategic
Scientific Initiatives, 31 Center Drive, Rm10A33, Bethesda, MD 20892 or
call non-toll-free number 301-547-9980 or Email your request, including
your address to: dickherberaj@mail.nih.gov. Formal requests for
additional plans and instruments must be requested in writing.
Proposed Collection: Surveys and Interviews to Support an
Evaluation of the Innovative Molecular Analysis Technologies (IMAT)
Program (NCI), 0925-0720, Expiration Date 5/31/2016--EXTENSION,
National Cancer Institute (NCI), National Institutes of Health (NIH).
Need and Use of Information Collection: The purpose of the proposed
evaluation is to pursue a comprehensive process and outcome assessment
of the 15-year old Innovative Molecular Analysis Technologies (IMAT)
program. While the program consistently offers promising indicators of
success, the full program has not been evaluated since 2008, and never
in as comprehensive a manner as has been formulated in the current
evaluation plan. An outcome evaluation of the long-standing National
Cancer Institute's (NCI) IMAT program presents a rich and unique
opportunity likely to serve institutes across the National Institutes
of Health (NIH), and perhaps other federal agencies, considering the
costs and benefits of directing resources towards supporting technology
development. An award through the NIH Evaluation Set-Aside program to
support this evaluation, for which NIH-wide relevance is a principle
element of determining merit for support, is testament to this. The
evaluation serves as an opportunity to gauge the impact of investments
in technology development and also to assess the strengths and
weaknesses of phased innovation award mechanisms. Prior approval from
OMB allowed for extensive surveys and interviews already, and this
extension is requested to accommodate unforeseen delays in collecting
the remaining information.
Like all institutes and centers (ICs) of the NIH, NCI seeks
opportunities for improving their programs' utility for the broad
continuum of researchers, clinicians and ultimately patients. NCI
Acting Director Douglas Lowy and other leadership across NCI, as well
as the NCI Board of Scientific Advisors, will be the primary users of
the evaluation results. Findings are primarily intended for considering
the long-term strategy to support innovative technology development and
how to more efficiently translate emerging capabilities through such
technologies into the promised benefits for cancer research and
clinical care. Interviews with grantees, program officers, review
officers, and other NIH awardees make up a crucial component of the
evaluation plan and will largely follow set survey protocols. Specific
near-term aims include the use of this information to consider the
utility of continued investment through existing solicitations and in
strategic planning generally for institute support for innovative
technology development.
OMB approval is requested for 1 year. There are no costs to
respondents other than their time. The total estimated annualized
burden hours are 233.

Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden Total annual
Form name Type of Number of responses per per response burden (in
respondents respondents respondent (in hours) hours)
----------------------------------------------------------------------------------------------------------------
Interview--IMAT Grantee....... IMAT Awardees... 18 1 1 18
Web-based Survey--Technology IMAT Awardees; 379 1 30/60 190
Grantees. Other NIH
Awardees
representing
comparison
group.
Interview--Tech End-Users..... Technology End- 50 1 30/60 25
Users.
---------------------------------------------------------------
Totals.................... ................ 447 447 .............. 233
----------------------------------------------------------------------------------------------------------------

[[Page 33264]]

Dated: May 19, 2016.
Karla Bailey,
Project Clearance Liaison, National Cancer Institute, NIH.
[FR Doc. 2016-12294 Filed 5-24-16; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.